Avalo Therapeutics Inc (NASDAQ: AVTX) kicked off on Friday, up 0.30% from the previous trading day, before settling in for the closing price of $6.73. Over the past 52 weeks, AVTX has traded in a range of $3.95-$34.46.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 31.22%. While this was happening, its average annual earnings per share was recorded 77.38%. With a float of $8.40 million, this company’s outstanding shares have now reached $9.68 million.
Let’s determine the extent of company efficiency that accounts for 19 employees. In terms of profitability, gross margin is 177.8%, operating margin of -3845.61%, and the pretax margin is -971.59%.
Avalo Therapeutics Inc (AVTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Avalo Therapeutics Inc is 19.68%, while institutional ownership is 55.13%. The most recent insider transaction that took place on Nov 13 ’24, was worth 6,500. In this transaction Director of this company bought 500 shares at a rate of $13.00, taking the stock ownership to the 1,000 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Director bought 500 for $12.50, making the entire transaction worth $6,250. This insider now owns 500 shares in total.
Avalo Therapeutics Inc (AVTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 77.38% per share during the next fiscal year.
Avalo Therapeutics Inc (NASDAQ: AVTX) Trading Performance Indicators
Take a look at Avalo Therapeutics Inc’s (AVTX) current performance indicators. Last quarter, stock had a quick ratio of 1.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 86.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -168.23, a number that is poised to hit -1.42 in the next quarter and is forecasted to reach -5.31 in one year’s time.
Technical Analysis of Avalo Therapeutics Inc (AVTX)
Looking closely at Avalo Therapeutics Inc (NASDAQ: AVTX), its last 5-days average volume was 0.1 million, which is a jump from its year-to-date volume of 99373.0. As of the previous 9 days, the stock’s Stochastic %D was 20.39%. Additionally, its Average True Range was 0.90.
During the past 100 days, Avalo Therapeutics Inc’s (AVTX) raw stochastic average was set at 7.59%, which indicates a significant decrease from 23.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.46% in the past 14 days, which was lower than the 94.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.69, while its 200-day Moving Average is $11.04. However, in the short run, Avalo Therapeutics Inc’s stock first resistance to watch stands at $7.04. Second resistance stands at $7.33. The third major resistance level sits at $7.83. If the price goes on to break the first support level at $6.25, it is likely to go to the next support level at $5.75. Now, if the price goes above the second support level, the third support stands at $5.46.
Avalo Therapeutics Inc (NASDAQ: AVTX) Key Stats
The company with the Market Capitalisation of 70.63 million has total of 10,394K Shares Outstanding. Its annual sales at the moment are 1,920 K in contrast with the sum of -31,540 K annual income. Company’s last quarter sales were recorded 250 K and last quarter income was 23,040 K.
